APA (7th ed.) Citation

X, S., L, Y., J, S., L, K., Z, Y., S, J., . . . C, F. (2022). Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. American journal of hematology, 97(5), 537. https://doi.org/10.1002/ajh.26486

Chicago Style (17th ed.) Citation

X, Shi, et al. "Anti-CD19 and Anti-BCMA CAR T Cell Therapy Followed by Lenalidomide Maintenance After Autologous Stem-cell Transplantation for High-risk Newly Diagnosed Multiple Myeloma." American Journal of Hematology 97, no. 5 (2022): 537. https://doi.org/10.1002/ajh.26486.

MLA (9th ed.) Citation

X, Shi, et al. "Anti-CD19 and Anti-BCMA CAR T Cell Therapy Followed by Lenalidomide Maintenance After Autologous Stem-cell Transplantation for High-risk Newly Diagnosed Multiple Myeloma." American Journal of Hematology, vol. 97, no. 5, 2022, p. 537, https://doi.org/10.1002/ajh.26486.